The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Lung Cancer MORE >>

Acquired resistance to tyrosine kinase inhibitors targeting EGFR mutations in patients with non–small cell lung cancer are leading to next-generation therapies equipped to circumvent the mutations that arise from initial treatment. A review of these mechanisms, and the latest agents being developed to address them, shows that the pipeline holds promise for the future.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.